Inavolisib, in combination with palbociclib (CDK4/6 inhibitor) and fulvestrant (estrogen-receptor antagonist), is approved for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative breast cancer [83]. Here, PIK3CA is linked to breast carcinoma.